Corresponding doses of mometasone furoate (MF) in once-daily inhaled fixed-dose combination (FDC) of indacaterol/mometasone furoate (IND/MF) and indacaterol/glycopyrronium/mometasone furoate (IND/GLY/MF): results from randomized clinical studies
IND/GLY/MF and IND/MF are both once-daily (o.d.) FDCs, recently approved for maintenance treatment of asthma. They have been developed with different MF doses with the goal to tailor therapy to a patient ’s needs. (Source: Journal of Allergy and Clinical Immunology)
Source: Journal of Allergy and Clinical Immunology - February 1, 2021 Category: Allergy & Immunology Authors: Roland Buhl, Huib Kerstjens, Ivan Nikolaev, Soniya Vaidya, Christian Bartels, Monish Jain, Juergen Jauernig, Ioannis Kottakis, Chenyu Qian, Hanns-Christian Tillman Source Type: research
Pharmacokinetics Of Indacaterol/Mometasone Furoate In Healthy Chinese Volunteers: Results From A Randomized, Open-label, Parallel-group Study
Once-daily indacaterol/mometasone furoate (IND/MF) is an inhaled long-acting β2-agonist/inhaled corticosteroid (LABA/ICS), recently approved for maintenance treatment of asthma. Pharmacokinetics of IND and MF after once-daily oral inhalation of IND/MF low- (150/80 μg), medium- (150/160 μg) and high-dose (150/320 μg) for 14 days were assessed in healthy Chinese volunteers . (Source: Journal of Allergy and Clinical Immunology)
Source: Journal of Allergy and Clinical Immunology - February 1, 2021 Category: Allergy & Immunology Authors: Yun Liu, Weie Cao, Yijun Wang, Soniya Vaidya, Jian Sun, Yingying Wang, Hanns-Christian Tillmann, Chenyu Qian Source Type: research
Cardiovascular safety of mometasone/indacaterol and mometasone/indacaterol/glycopyrronium once-daily fixed-dose combinations in asthma
To evaluate cardiovascular safety of two new inhaled fixed-dose combinations for treatment of asthma: (i) the inhaled corticosteroid/long-acting beta2-agonist (ICS/LABA) mometasone furoate/indacaterol acetate (MF/IND), (ii) the ICS/LABA/long-acting muscarinic antagonist (LAMA) MF/IND/glycopyrronium bromide (GLY). (Source: Respiratory Medicine)
Source: Respiratory Medicine - January 27, 2021 Category: Respiratory Medicine Authors: Emil Scosyrev, Richard van Zyl-Smit, Huib Kerstjens, Christian Gessner, Oliver Kornmann, Devendra Jain, Elodie Aubrun, Peter D ’Andrea, Motoi Hosoe, Abhijit Pethe, Dominic Brittain Tags: Original Research Source Type: research
P-glycoprotein inhibition with verapamil overcomes mometasone resistance in Chronic Sinusitis with Nasal Polyps.
CONCLUSIONS: Our study confirms that P-gp contributes to mometasone resistance. This P-gp mediated resistance was successfully reversed by addition of the P-gp inhibitor verapamil. Verapamil further significantly enhanced the anti-inflammatory effect of mometasone when given as a combination therapy.
PMID: 33459729 [PubMed - as supplied by publisher] (Source: Rhinology)
Source: Rhinology - January 21, 2021 Category: ENT & OMF Tags: Rhinology Source Type: research
Dupilumab improves upper- and lower-airway disease control in chronic rhinosinusitis with nasal polyps and asthma.
CONCLUSION: Dupilumab improved upper- and lower-airway outcome measures and HRQoL in patients with severe CRSwNP and comorbid asthma, and was well tolerated.
PMID: 33465455 [PubMed - as supplied by publisher] (Source: Annals of Allergy, Asthma and Immunology)
Source: Annals of Allergy, Asthma and Immunology - January 16, 2021 Category: Allergy & Immunology Authors: Laidlaw TM, Bachert C, Amin N, Desrosiers M, Hellings PW, Mullol J, Maspero JF, Gevaert P, Zhang M, Mao X, Khan AH, Kamat S, Patel N, Graham NMH, Ruddy M, Staudinger H, Mannent LP Tags: Ann Allergy Asthma Immunol Source Type: research
Simultaneous Determination of Mometasone Furoate and Salicylic Acid in Complex Matrix Using Green Analytical Method
Publication date: Available online 25 December 2020Source: Microchemical JournalAuthor(s): Amira F. El-Yazbi, Faten M. Aboukhalil, Essam F. Khamis, Rasha M. Youssef, Mahmoud A. El-Sayed (Source: Microchemical Journal)
Source: Microchemical Journal - December 26, 2020 Category: Chemistry Source Type: research
Treatment of allergic rhinitis during and outside the pollen season using mobile technology. A MASK study
ConclusionsThis study shows that the overall efficacy of treatments is similar during and outside the pollen season and indicates that medications are similarly effective during the year. (Source: Clinical and Translational Allergy)
Source: Clinical and Translational Allergy - December 9, 2020 Category: Allergy & Immunology Source Type: research
P450 clinical measures of asthma control from the mometasone furoate/formoterol spiro trial
Asthma maintenance treatment aims to preserve asthma control in order to reduce the risk of asthma exacerbation. The combination between an inhaled corticosteroid and a fast-acting bronchodilator, systemic corticosteroids (SCS) bursts and other add-on asthma medications are prescribed for asthma worsening to mitigate serious outcomes.1 Primary findings from a 26-week double-blind, randomized-controlled trial in patients ≥12 years of age with persistent asthma comparing mometasone furoate/formoterol (MF/F) to MF did not demonstrate a significant difference in asthma-related hospitalizations, intubations and deaths, but di...
Source: Annals of Allergy, Asthma and Immunology - November 1, 2020 Category: Allergy & Immunology Authors: C. Weinstein, D. Gates, X. Zhang, S. Lane, I. Agache, R. Nathan Tags: Pharmacology and Pharmacotherapeutics Source Type: research
P509 reslizumab an interleukin-5 antagonist monoclonal antibody for uncontrolled chronic rhinosinusitis with nasal polyps
Previously, we demonstrated that the addition of subcutaneous Dupilumab to intranasal corticosteroid has additive beneficial effects for uncontrolled chronic rhinosinusitis with nasal polyps (CRSwNP). Clinical observations led us to believe that the addition of intravenous Reslizumab, an interleukin-5 antagonist monoclonal antibody (IgG4 kappa), may provide additional efficacy in sub optimally controlled CRSwNP despite daily use of intranasal glucocorticosteroid (INCS) Mometasone furoate with interval necessity of systemic corticosteroids for breakthrough relief. (Source: Annals of Allergy, Asthma and Immunology)
Source: Annals of Allergy, Asthma and Immunology - November 1, 2020 Category: Allergy & Immunology Authors: S. Nsouli Source Type: research
Indacaterol/mometasone furoate combination: synergism in human hyperresponsive airway smooth muscle
Conclusion: IND/MF combination synergistically relaxed hyperresponsive human ASM in ex vivo models of bronchial asthma.Funding: This study was supported by Novartis Pharma AG, Basel, Switzerland. (Source: European Respiratory Journal)
Source: European Respiratory Journal - October 28, 2020 Category: Respiratory Medicine Authors: Calzetta, L., Ritondo, B. L., Nikolaev, I., Cazzola, M., Matera, M. G., Rogliani, P. Tags: Airway pharmacology and treatment Source Type: research
IND/GLY/MF: synergism in medium and small human hyperresponsive airways
Conclusion: IND/GLY/MF synergistically relaxed hyperresponsive human isolated medium and small airways in ex vivo models of bronchial asthma.Funding: This study was supported by Novartis Pharma AG, Basel, Switzerland. (Source: European Respiratory Journal)
Source: European Respiratory Journal - October 28, 2020 Category: Respiratory Medicine Authors: Rogliani, P., Ritondo, B. L., Nikolaev, I., Cazzola, M., Matera, M. G., Calzetta, L. Tags: Airway pharmacology and treatment Source Type: research
Effectiveness of skin protectors and calendula officinalis for prevention and treatment of radiodermatitis: an integrative review.
CONCLUSION: data confirm the potential of Calendula officinalis for prevention and treatment of radiodermatitis and point to promising results regarding skin protector use; however, there is a need for further testing as to the effectiveness of such products.
PMID: 33084806 [PubMed - in process] (Source: Revista Brasileira de Enfermagem)
Source: Revista Brasileira de Enfermagem - October 23, 2020 Category: Nursing Authors: Simões FV, Santos VO, Silva RND, Silva RCD Tags: Rev Bras Enferm Source Type: research
Corrigendum to “Fixed-dose combination of indacaterol/glycopyrronium/mometasone furoate once-daily versus salmeterol/fluticasone twice-daily plus tiotropium once-daily in patients with uncontrolled asthma: A randomised, Phase IIIb, non-inferiority study (ARGON)” [Respir. Med. 170 (Aug-Sep 2020) 106021]
Two instances of data have been updated in Table 2 (Page 8) of the publication, following an amendment in the Clinical Study Report. Asthma (severe exacerbation) data in the column of IND/GLY/MF high-dose o.d. (N = 476) changed from 2 (0.4) to 3 (0.6) and added data on Supraventricular tachycardia: IND/GLY/MF medium-dose o.d., 0; IND/GLY/MF high-dose o.d., 1 (0.2); SAL/FLU high-dose b. i.d.+TIO o. d. 0. (Source: Respiratory Medicine)
Source: Respiratory Medicine - October 18, 2020 Category: Respiratory Medicine Authors: Christian Gessner, Oliver Kornmann, Jorge Maspero, Richard van Zyl-Smit, Matthias Kr üll, Anna Salina, Pritam Gupta, Sebastien Bostel, Sebastian Fucile, Lorena Garcia Conde, Pascal Pfister Source Type: research
Inhaled Corticosteroids and Endocrine Effects in Childhood
This article reviews 4 areas critical to understanding potential adverse endocrine outcomes of ICSs and placing them in proper perspective: (1) influence of drug/delivery device properties on systemic steroid burden; (2) adrenal insufficiency during ICS treatment; (3) growth effects of ICS and asthma itself; and (4) bone mineral accretion during ICS therapy. (Source: Endocrinology and Metabolism Clinics of North America)
Source: Endocrinology and Metabolism Clinics of North America - October 13, 2020 Category: Endocrinology Authors: David B. Allen Source Type: research
Pharmacokinetics of indacaterol, glycopyrronium and mometasone furoate following once-daily inhalation as a combination in healthy subjects
Publication date: Available online 6 October 2020Source: Pulmonary Pharmacology & TherapeuticsAuthor(s): Soniya Vaidya, Juergen Jauernig, Brian Ethell, Nasri Abdallah, Surendra Machineni, Anton Drollmann, Olivier Heudi, Stefanie Last, Michael Hahn, Rajkumar Radhakrishnan, Stanislav Ignatenko, Hanns-Christian Tillmann (Source: Pulmonary Pharmacology and Therapeutics)
Source: Pulmonary Pharmacology and Therapeutics - October 8, 2020 Category: Respiratory Medicine Source Type: research
